Please assess the completion status of the following clinical trial:

Trial Title: Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient older than 18 years~* Inoperable (advanced or metastatic) HCC histologically proven, or diagnosed according to the Barcelona criteria, determined to be candidate for Sorafenib therapy~* Lesion(s) able to be selected as targeted lesion(s) for modified RECIST criteria~* patient ineligible for curative treatment~* Child-Pugh liver function (platelet count superior or equal to 60X1 000 000 000per liter; haemoglobin superior or equal to 8,5g/dl~* Performance status more or equal to 2~* Able to lie still for 45min for PET/CT scanning~* Able to understand and willing to signa written informed consent document~* Affiliated to the French social security social or beneficiary to such a regimen~Exclusion Criteria:~* Uncontrolled intercurrent illness with short-term life-threatening~* Pregnant or nursing woman~* Patient candidate to local/curative therapy of HCC (surgery, radiofrequency, transarterial chemoembolization, other local therapy).~* History of myocardial infarction less than 6 months before inclusion, uncontrolled hypertension, symptomatic congestive heart failure, anti-arrhythmic therapy (other than beta-blockers or digoxine)~* History of digestive bleeding less than 30 days before inclusion~* history of liver transplantation~* Previous treatment including Sorafenib Uncontrolled diabetes History of allergic reactions attributed to compounds of similar chemical or biologic composition to Fluorocholine, 18F-Fluorodeoxyglucose or Sorafenib~* Psychiatric illness/social situations that would limit compliance with the study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- FDG and FCH PET (Type: EXPERIMENTAL): Patients will performed a TEP with 2 different radiotracer before treatment is started and 1 month after treatment has been started.

Based on this trial design, predict the completion outcome and termination type (if applicable).